Clinical Trial Results:
A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally
advanced, recurrent, or metastatic breast cancer
STRIDE - STimulating immune Response In aDvanced brEast cancer
Summary
|
|
EudraCT number |
2008-005544-17 |
Trial protocol |
CZ SE BE DE HU NL IE AT PT FR IT SK GR ES |
Global completion date |
10 Sep 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jun 2016
|
First version publication date |
29 Jun 2016
|
Other versions |
|
Summary report(s) |
2008-005544-17_CT.gov results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.